Hagens Berman notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the September 28, 2026 lead plaintiff deadline in the pending securities class action.

Submit Your CAPR Losses To HBSS

Key Details

• Class Period: Dec. 17, 2025 – July 26, 2026
• Lead Plaintiff Deadline: Sept. 28, 2026
• Visit: www.hbsslaw.com/capr
• Contact the Firm Now: CAPR@hbsslaw.com / 844-916-0895
• View our latest video summary of the allegations: youtu.be/-lnVTKgV6as

Core Allegations

The lawsuit alleges that Capricor misrepresented clinical trial data and the regulatory pathway for its lead product candidate, Deramiocel, intended to treat Duchenne muscular dystrophy (DMD). Specifically, Defendants allegedly failed to disclose that they adopted changes to the pre-specified statistical analysis plan (SAP) without agreement from the FDA prior to resubmitting its Biologics License Application.

On July 27, 2026, the FDA published briefing documents that revealed that Capricor made unagreed-upon post-hoc modifications to its SAP. The FDA stated that the HOPE-3 study “did not meet its pre-specified primary and secondary efficacy endpoints showing no statistically significant difference between deramiocel and placebo at 12 months.” Capricor shares immediately crashed roughly 64%.

If you’d like more information and answers to frequently asked questions about the Capricor case and the firm’s investigation, read more »

Whistleblowers: Persons with non-public information regarding Capricor should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email CAPR@hbsslaw.com.

About Hagens Berman

Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.

Attorney Advertising. Prior results do not guarantee a similar outcome in any future case.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260923807840/en/

“We're focused on investors’ losses and uncovering the full scope of how management characterized these trial endpoints and undisclosed modification,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.